Initial public offerings in the biotech sector nosedived last year after a lot of activity in 2021, but have remained few and far between this year amid tough economic con
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh